Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytomX TherapeuticsCTMX -1.23%36 Cash Ratio is 10.19 as of Mar. 2026, which is 190% above its 10-year median of 3.51. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,385 Biotechnology companies, CytomX Therapeutics ranks better than 81.23% on this metric.
CytomX Therapeutics has a Cash Ratio of 10.19. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for CytomX Therapeutics's Cash Ratio or its related term are showing as below:
CTMX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.96 Med: 3.51 Max: 10.19
Current: 10.19
During the past 13 years, CytomX Therapeutics's highest Cash Ratio was 10.19. The lowest was 0.96. And the median was 3.51.
CTMX's Cash Ratio is ranked better than 81.23% of 1385
companies
in the Biotechnology industry
Industry Median: 2.95
vs CTMX: 10.19
CytomX Therapeutics (NAS:CTMX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
CytomX Therapeutics Cash Ratio Related Terms
CytomX Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for CytomX Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CytomX Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytomX Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where CytomX Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytomX Therapeutics (CTMX) has a Cash Ratio of 10.19 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on CytomX Therapeutics and its competitors. This is 190% above median its historical median of 3.51. Over the past decade, CytomX Therapeutics' Cash Ratio has ranged from 0.96 to 10.19. According to the industry distribution chart, CytomX Therapeutics ranks #260 out of 1385 companies in the Biotechnology industry, placing it in the top 18.8%.
Is CytomX Therapeutics' Cash Ratio too high?
CytomX Therapeutics' current Cash Ratio of 10.19 is 190% above median its 10-year median of 3.51. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 10.19. The Biotechnology industry median Cash Ratio is 2.95. CytomX Therapeutics' value of 10.19 is 245.4% above this industry median. Based on the distribution chart, CytomX Therapeutics ranks #260 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Cash Ratio compare to ALLO and XOMA?
According to the Biotechnology industry distribution chart, CytomX Therapeutics ranks #260 out of 1385 companies for Cash Ratio. This places CytomX Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.95. CytomX Therapeutics' value of 10.19 is 245.4% above this benchmark. Historically, CytomX Therapeutics' own Cash Ratio has ranged from 0.96 to 10.19 over the past decade. While the company's 10-year median is 3.51 vs. the industry median of 2.95, CytomX Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytomX Therapeutics's current Cash Ratio of 10.19 is 245.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on CytomX Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytomX Therapeutics's current Cash Ratio is 10.19, which is 190% above median its own 10-year median of 3.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.62 — trading 1192.9% above its estimated fair value. The current Cash Ratio is 10.19, which is 190% above median its 10-year median of 3.51 and 245.4% above the Biotechnology industry median of 2.95. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Cash Ratio is 10.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytomX Therapeutics (CTMX) Overvalued in 2026?
Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued.
The current stock price of $3.62 is trading 1192.9% above its estimated GF Value™ of $0.28.
GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.
Key valuation signals for CTMX:
Cash Ratio: 10.19 (190% above median its 10-year median of 3.51)
GF Value™: $0.28 vs. price of $3.62 (1192.9% above fair value)
Industry Position: 245.4% above the Biotechnology median (#260 of 1385)
No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score
Get the complete analysis for CTMX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTMX has been successfully added to your 
